Plus Therapeutics Stock Number Of Shares Shorted

PSTV Stock

USD 1.29 0.01 0.78%

Plus Therapeutics fundamentals help investors to digest information that contributes to Plus Therapeutics' financial success or failures. It also enables traders to predict the movement of Plus Stock. The fundamental analysis module provides a way to measure Plus Therapeutics' intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Plus Therapeutics stock.

Short Long Term Debt Total Total Assets

This module does not cover all equities due to inconsistencies in global equity categorizations. Continue to Equity Screeners to view more equity screening tools.

Plus Therapeutics Company Number Of Shares Shorted Analysis

Plus Therapeutics' Number of Shares Shorted is the total amount of shares that are currently sold short by investors. When a stock is sold short, the short seller assumes the responsibility of repurchasing the stock at a lower price. The speculator will make money if the stock goes down in price or will experience a loss if the stock price goes up.

Shares Shorted

Shorted by Public

+

by Institutions

More About Number Of Shares Shorted | All Equity Analysis

Current Plus Therapeutics Number Of Shares Shorted

103.98 K

Most of Plus Therapeutics' fundamental indicators, such as Number Of Shares Shorted, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Plus Therapeutics is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.

Plus Number Of Shares Shorted Driver Correlations

Understanding the fundamental principles of building solid financial models for Plus Therapeutics is extremely important. It helps to project a fair market value of Plus Stock properly, considering its historical fundamentals such as Number Of Shares Shorted. Since Plus Therapeutics' main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of Plus Therapeutics' historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of Plus Therapeutics' interrelated accounts and indicators.

	Total Assets	Total Stockholder Equity	Net Debt	Total Liab	Total Current Assets	Retained Earnings	Net Receivables	Short Term Debt	Common Stock	Current Deferred Revenue	Accounts Payable	Intangible Assets	Good Will	Net Tangible Assets	Long Term Debt	Long Term Debt Total	Capital Surpluse	Property Plant Equipment	Net Invested Capital	Net Working Capital	Capital Stock
Total Assets		0.43	0.17	0.86	0.85	0.08	0.69	0.15	0.6	0.34	0.5	0.45	0.54	-0.17	0.48	0.53	-0.55	-0.27	0.65	-0.26	0.29
Total Stockholder Equity	0.43		-0.2	-0.04	0.32	-0.07	0.04	0.04	0.3	0.18	0.23	0.12	0.23	0.44	-0.06	-0.01	-0.03	0.1	0.42	0.1	0.38
Net Debt	0.17	-0.2		0.24	-0.3	0.17	0.24	0.4	0.31	-0.39	-0.04	0.79	0.43	-0.43	0.16	0.26	-0.29	0.08	0.44	-0.69	-0.13
Total Liab	0.86	-0.04	0.24		0.81	0.05	0.7	0.13	0.49	0.27	0.49	0.37	0.43	-0.39	0.5	0.53	-0.55	-0.31	0.41	-0.34	0.07
Total Current Assets	0.85	0.32	-0.3	0.81		0.02	0.63	-0.06	0.37	0.51	0.5	0.03	0.29	-0.05	0.45	0.44	-0.45	-0.37	0.33	0.03	0.22
Retained Earnings	0.08	-0.07	0.17	0.05	0.02		0.45	-0.3	0.18	0.47	-0.8	0.46	0.74	-0.19	0.8	0.81	-0.83	-0.58	0.64	-0.42	0.11
Net Receivables	0.69	0.04	0.24	0.7	0.63	0.45		-0.01	0.35	0.21	0.07	0.53	0.59	-0.22	0.78	0.78	-0.77	-0.61	0.56	-0.34	0.05
Short Term Debt	0.15	0.04	0.4	0.13	-0.06	-0.3	-0.01		-0.16	-0.3	0.36	0.2	-0.11	-0.41	-0.42	-0.34	0.18	0.63	0.05	-0.33	-0.25
Common Stock	0.6	0.3	0.31	0.49	0.37	0.18	0.35	-0.16		0.03	0.16	0.6	0.58	0.2	0.47	0.52	-0.45	-0.16	0.57	-0.3	0.26
Current Deferred Revenue	0.34	0.18	-0.39	0.27	0.51	0.47	0.21	-0.3	0.03		-0.18	-0.23	0.32	-0.04	0.45	0.45	-0.45	-0.37	0.27	-0.18	0.06
Accounts Payable	0.5	0.23	-0.04	0.49	0.5	-0.8	0.07	0.36	0.16	-0.18		-0.17	-0.34	0.04	-0.37	-0.36	0.37	0.3	-0.23	0.15	-0.05
Intangible Assets	0.45	0.12	0.79	0.37	0.03	0.46	0.53	0.2	0.6	-0.23	-0.17		0.78	-0.28	0.52	0.62	-0.63	-0.23	0.79	-0.63	0.19
Good Will	0.54	0.23	0.43	0.43	0.29	0.74	0.59	-0.11	0.58	0.32	-0.34	0.78		-0.3	0.78	0.85	-0.83	-0.45	0.88	-0.56	0.2
Net Tangible Assets	-0.17	0.44	-0.43	-0.39	-0.05	-0.19	-0.22	-0.41	0.2	-0.04	0.04	-0.28	-0.3		-0.17	-0.2	0.3	0.07	-0.23	0.35	0.13
Long Term Debt	0.48	-0.06	0.16	0.5	0.45	0.8	0.78	-0.42	0.47	0.45	-0.37	0.52	0.78	-0.17		0.99	-0.92	-0.82	0.66	-0.36	0.13
Long Term Debt Total	0.53	-0.01	0.26	0.53	0.44	0.81	0.78	-0.34	0.52	0.45	-0.36	0.62	0.85	-0.2	0.99		-0.94	-0.77	0.74	-0.47	0.16
Capital Surpluse	-0.55	-0.03	-0.29	-0.55	-0.45	-0.83	-0.77	0.18	-0.45	-0.45	0.37	-0.63	-0.83	0.3	-0.92	-0.94		0.64	-0.8	0.46	-0.22
Property Plant Equipment	-0.27	0.1	0.08	-0.31	-0.37	-0.58	-0.61	0.63	-0.16	-0.37	0.3	-0.23	-0.45	0.07	-0.82	-0.77	0.64		-0.34	0.1	-0.23
Net Invested Capital	0.65	0.42	0.44	0.41	0.33	0.64	0.56	0.05	0.57	0.27	-0.23	0.79	0.88	-0.23	0.66	0.74	-0.8	-0.34		-0.43	0.38
Net Working Capital	-0.26	0.1	-0.69	-0.34	0.03	-0.42	-0.34	-0.33	-0.3	-0.18	0.15	-0.63	-0.56	0.35	-0.36	-0.47	0.46	0.1	-0.43		0.25
Capital Stock	0.29	0.38	-0.13	0.07	0.22	0.11	0.05	-0.25	0.26	0.06	-0.05	0.19	0.2	0.13	0.13	0.16	-0.22	-0.23	0.38	0.25

Click cells to compare fundamentals

If a large number of investors decide to short sell an equity instrument within a small period of time, their combined action can significantly affect the price of the stock.

Competition

Predict Plus Therapeutics

Based on the recorded statements, Plus Therapeutics has 103.98 K of outstending shares currently sold short by investors. This is 96.75% lower than that of the Biotechnology sector and 97.96% lower than that of the Health Care industry. The number of shares shorted for all United States stocks is 97.79% higher than that of the company.

Plus Number Of Shares Shorted Peer Comparison

Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Plus Therapeutics' direct or indirect competition against its Number Of Shares Shorted to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Plus Therapeutics could also be used in its relative valuation, which is a method of valuing Plus Therapeutics by comparing valuation metrics of similar companies.

Plus Therapeutics is currently under evaluation in number of shares shorted category among its peers.

Plus Fundamentals

	Return On Equity	-5.22
	Return On Asset	-0.69
	Profit Margin	(2.40) %
	Operating Margin	(2.89) %
	Current Valuation	6.16 M
	Shares Outstanding	5.9 M
	Shares Owned By Insiders	2.34 %
	Shares Owned By Institutions	11.30 %
	Number Of Shares Shorted	103.98 K
	Price To Book	3.76 X
	Price To Sales	1.38 X
	Revenue	4.91 M
	Gross Profit	(9.47 M)
	EBITDA	(12.69 M)
	Net Income	(13.32 M)
	Cash And Equivalents	20.27 M
	Cash Per Share	0.60 X
	Total Debt	4.18 M
	Debt To Equity	0.53 %
	Current Ratio	2.81 X
	Book Value Per Share	(0.30) X
	Cash Flow From Operations	(12.85 M)
	Short Ratio	0.98 X
	Earnings Per Share	(2.37) X
	Target Price	16.0
	Number Of Employees	20
	Beta	0.69
	Market Capitalization	7.61 M
	Total Asset	11.39 M
	Retained Earnings	(480.5 M)
	Working Capital	(893 K)
	Net Asset	11.39 M

About Plus Therapeutics Fundamental Analysis

The Macroaxis Fundamental Analysis modules help investors analyze Plus Therapeutics's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Plus Therapeutics using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Plus Therapeutics based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.

Please read more on our fundamental analysis page.

Thematic Opportunities

Explore Investment Opportunities

Build portfolios using Macroaxis predefined set of investing ideas. Many of Macroaxis investing ideas can easily outperform a given market. Ideas can also be optimized per your risk profile before portfolio origination is invoked. Macroaxis thematic optimization helps investors identify companies most likely to benefit from changes or shifts in various micro-economic or local macro-level trends. Originating optimal thematic portfolios involves aligning investors' personal views, ideas, and beliefs with their actual investments.

Explore Investing Ideas

Additional Tools for Plus Stock Analysis

When running Plus Therapeutics' price analysis, check to measure Plus Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Plus Therapeutics is operating at the current time. Most of Plus Therapeutics' value examination focuses on studying past and present price action to predict the probability of Plus Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Plus Therapeutics' price. Additionally, you may evaluate how the addition of Plus Therapeutics to your portfolios can decrease your overall portfolio volatility.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC